Entrada Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Entrada Therapeutics Capital Expenditures (CapEx) Growth & History (TRDA)
Entrada Therapeutics's capital expenditures (capex) was $1.0M for fiscal 2025.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.0M | −$2.1M | −67.04% |
| 2024 | 2024-12-31 | $3.2M | −$2.5M | −43.75% |
| 2023 | 2023-12-31 | $5.6M | $2.7M | +94.46% |
| 2022 | 2022-12-31 | $2.9M | −$1.7M | −36.97% |
| 2021 | 2021-12-31 | $4.6M | $2.3M | +97.58% |
| 2020 | 2020-12-31 | $2.3M | — | — |
Entrada Therapeutics quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11,000 | −$264,000 | −96.00% |
| Q1 2026 | 2026-03-31 | $44,000 | −$1.1M | −96.15% |
| Q4 2025 | 2025-12-31 | $207,000 | −$428,000 | −67.40% |
| Q3 2025 | 2025-09-30 | $171,000 | −$468,000 | −73.24% |
| Q2 2025 | 2025-06-30 | $275,000 | −$771,000 | −73.71% |
| Q1 2025 | 2025-03-31 | $1.1M | $306,000 | +36.52% |
| Q4 2024 | 2024-12-31 | $635,000 | −$341,000 | −34.94% |
| Q3 2024 | 2024-09-30 | $639,000 | −$809,000 | −55.87% |
| Q2 2024 | 2024-06-30 | $1.0M | −$476,000 | −31.27% |
| Q1 2024 | 2024-03-31 | $838,000 | −$830,000 | −49.76% |
| Q4 2023 | 2023-12-31 | $976,000 | $268,000 | +37.85% |
| Q3 2023 | 2023-09-30 | $1.4M | $638,000 | +78.77% |
| Q2 2023 | 2023-06-30 | $1.5M | $747,000 | +96.39% |
| Q1 2023 | 2023-03-31 | $1.7M | $1.1M | +180.81% |
| Q4 2022 | 2022-12-31 | $708,000 | −$614,000 | −46.44% |
| Q3 2022 | 2022-09-30 | $810,000 | $4,000 | +0.50% |
| Q2 2022 | 2022-06-30 | $775,000 | −$769,000 | −49.81% |
| Q1 2022 | 2022-03-31 | $594,000 | −$314,000 | −34.58% |
| Q4 2021 | 2021-12-31 | $1.3M | — | — |
| Q3 2021 | 2021-09-30 | $806,000 | — | — |
| Q2 2021 | 2021-06-30 | $1.5M | — | — |
| Q1 2021 | 2021-03-31 | $908,000 | — | — |
Entrada Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Entrada Therapeutics's capital expenditures (capex) decreased from $2.3M to $1.0M, a change of −$1.3M. The latest reported quarter, Q2 2026, shows $11,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics source filings ↗